Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2008-06-03
2008-06-03
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100
Reexamination Certificate
active
07381410
ABSTRACT:
In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
REFERENCES:
patent: 5512591 (1996-04-01), Halperin et al.
patent: 5624899 (1997-04-01), Bennett
patent: 5635177 (1997-06-01), Bennett
patent: 5693762 (1997-12-01), Queen et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5795734 (1998-08-01), Flanagan et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5864020 (1999-01-01), Bennett
patent: 6015711 (2000-01-01), Olson et al.
patent: 6303769 (2001-10-01), Cerretti
patent: 6413730 (2002-07-01), Holland
patent: 6440954 (2002-08-01), Haber et al.
patent: 6479459 (2002-11-01), Cerretti
patent: 6492140 (2002-12-01), Cerretti
patent: 6514497 (2003-02-01), Briskin et al.
patent: 6579683 (2003-06-01), Wang et al.
patent: 6864227 (2005-03-01), Wang et al.
patent: 6887674 (2005-05-01), Wang et al.
patent: 6916625 (2005-07-01), Wang et al.
patent: 2002/0136726 (2002-09-01), Anderson et al.
patent: 2002/0146420 (2002-10-01), Bennett
patent: 2004/0110150 (2004-06-01), Koller et al.
patent: 2004/0234520 (2004-11-01), Aguet et al.
patent: 2004/0247592 (2004-12-01), Roifman et al.
patent: 2005/0204412 (2005-09-01), Wang et al.
patent: 2006/0035328 (2006-02-01), Wang et al.
patent: 633 315 (1995-01-01), None
patent: WO 93/00425 (1993-01-01), None
patent: WO-93/15201 (1993-08-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11020 (1994-05-01), None
patent: WO-95/27061 (1995-10-01), None
patent: WO-96/01839 (1996-01-01), None
patent: WO-96/02645 (1996-02-01), None
patent: WO 96/03043 (1996-02-01), None
patent: WO 96/09384 (1996-03-01), None
patent: WO 96/13518 (1996-05-01), None
patent: WO 96/23000 (1996-08-01), None
patent: WO-96/26958 (1996-09-01), None
patent: WO 96/36713 (1996-11-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/23629 (1997-07-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO-98/01548 (1998-01-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO-98/45708 (1998-10-01), None
patent: WO-99/08696 (1999-02-01), None
patent: WO 99/17796 (1999-04-01), None
patent: WO 99/52541 (1999-10-01), None
patent: 0999 278 (2000-05-01), None
patent: WO-00/24413 (2000-05-01), None
patent: WO-00/30673 (2000-06-01), None
patent: WO-02/11785 (2002-02-01), None
patent: WO-02/26827 (2002-04-01), None
patent: WO 2005/051307 (2002-06-01), None
patent: WO-02/058538 (2002-08-01), None
patent: WO-02/061055 (2002-08-01), None
patent: WO-02/079382 (2002-10-01), None
patent: WO-02/102854 (2002-10-01), None
patent: WO-02/102972 (2002-12-01), None
patent: WO-02/102973 (2002-12-01), None
patent: WO-03/004057 (2003-01-01), None
patent: WO 03/094859 (2003-11-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 2004/024773 (2004-03-01), None
patent: WO 2004/024773 (2004-03-01), None
patent: WO 2004/080425 (2004-09-01), None
patent: WO 2004/080425 (2004-09-01), None
patent: WO 2004/091375 (2004-10-01), None
patent: WO 2005/048917 (2005-06-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042.).
Stephenson et al (BMC Molecular Biology, Dec. 21, 2001, 2(15):1-9).
Kitamura et al (Cancer Research, Aug. 15, 1991, 51:4310-4315).
Inada et al., “Selective Expression of the Receptor Tyrosine Kinase, HTK, on Human Erythroid Progenitor Cells”, Blood, 89(8), pp. 2757-2765 (1997).
Santa Cruz Biotechnology, Inc., “EphB4 (N-19): sc-7285”, retrieved from the Internet: URL:http://www.genetimes.com.cn/support/pd f-ds/7200-7299/sc-7285.pdf (1999).
Sinha, et al., “Expression of EphB4 in head and neck squamous cell carcinoma” Ear, Nose and Throat Journal, 82(11), pp. 866-870 & 887 (2003).
Adams, R.H., et al., “Roles of ephrinB ligands of EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiognesis.” Genes Dev. 13:295-306 (1999).
Berclaz, G., et al., “Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma,”0 Ann Oncol., 14:220-226 (2003).
Berclaz, G., et al., “Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium,” Biochem Biophys Res Commun., 24;226:869-875 (1996).
Brambilla, R., et al., “Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases,” EMBO J., 14:3116-3126 (1995).
Bruhl, T., et al., “Homeobox A9 Transcriptionally Regulates the EphB4 Receptor to Modulate Endothelial Cell Migration and Tube Formation,” Circ. Res., 743-751 (2004) [Epub ahead of print] DOI 10.1161/01res0000120861.27064.09.
Carbone, M., et al., “The pathogenesis of mesothelioma,” Semin. Oncol., 29(1):2-17 (2002).
Cheng, N., et al., “The ephrins and Eph receptors in angiogenesis,” Cytokine & Growth Factor Reviews, 13:75-85 (2002).
Cowan, C.A., et al., “Ephrins in reverse, park and drive,” Trends in Cell Biology, 12(7):339-346 (2002).
Davis, S., et al., “Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity,” Science, 266(5186):816-819 (1994).
Fuller, T., et al., “Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells, ” J. Cell Sci., 6 (2003).
Gerety, S.S., et al., “Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development,” Mol. Cell, 4:403-414 (1999).
Hamada, K., et al., “Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells,” Arterioscler. Thromb. Vasc. Biol., 23:190-197 (2003).
Himanen, J.P. et al., “Eph signaling: a structural view,” Trends in Neurosciences, 26(1):46-51 (2003).
Himanen, J.P., et al., “Eph receptors and ephrins,” Intl. J. Biochem. & Cell Bio., 35:130-134 (2003).
Hirai, H., “A novel putative tyrosine kinase receptor encoded by the eph gene,” Science, 238:1717-1720 (1987).
Kiyokawa, E., et al., “Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors,” Cancer Res., 54:3645-3650 (1994).
Kullander, K., et al., “Mechanisms and functions of eph and ephrin signalling,” Nature Reviews, Molecular Cell biology, 3:475-486 (2002).
Mellizer, G., et al., “Control of cell behavior by signalling through Eph receptors and ephrins,” Neurobiology, 10:400-408 (2000).
Munarini, N., et al., “Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase, ” J. Cell Sci., 115(pt 1):25-37 (2002).
Nomura, A.M., et al., “Prostate cancer: a current perspective,” Epidemiol Rev., 13:200-227 (1991).
Pasquale, E.B., “The Eph family of receptors,” Curr. Opin. Cell Biol., 9:608-615 (1997).
Sakano, S., et al., “Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells,” Oncogene., 13:813-822 (1996).
Schmucker, D., et al., “Signaling Downstream of Eph Receptors and Ephrin Ligands,” Cell, 105:701-704 (2001).
Shin, D., et al., “Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization,” Dev. Biol. 230:139-150 (2001).
Sinha, U.K., et al., “Expression of EphB4 in head and neck squamous cell carcinoma,” ENT J 82:721-723 (2003).
Steinle, J.J., et al., “Eph B4
Gill Parkash
Kertesz Nathalie
Krasnoperov Valery
Reddy Ramachandra
Zozulya Sergey
Aeder Sean E
Ropes & Gray LLP
VasGene Therapeutics, Inc.
Yu Misook
LandOfFree
Polypeptide compounds for inhibiting angiogenesis and tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide compounds for inhibiting angiogenesis and tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide compounds for inhibiting angiogenesis and tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2811317